Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - tyverb
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp98293235ce75cd341e491c62f161e333
identifier: http://ema.europa.eu/identifier
/EU/1/07/440/001-007
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Tyverb 250 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-98293235ce75cd341e491c62f161e333
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/07/440/001-007
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - tyverb
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
Tyverb is used to treat certain types of breast cancer (HER2-overexpressing) which have spread beyond the original tumour or to other organs (advanced or metastatic breast cancer). It may slow or stop cancer cells from growing, or may kill them.
Tyverb is prescribed to be taken in combination with another anti-cancer medicine.
Tyverb is prescribed in combination with capecitabine, for patients who have had treatment for advanced or metastatic breast cancer before. This previous treatment for metastatic breast cancer must have included trastuzumab.
Tyverb is prescribed in combination with trastuzumab, for patients who have hormone receptor- negative metastatic breast cancer and have had other treatment for advanced or metastatic breast cancer before.
Tyverb is prescribed in combination with an aromatase inhibitor, for patients with hormone sensitive metastatic breast cancer (breast cancer that is more likely to grow in the presence of hormones), who are not currently intended for chemotherapy.
Information about these medicines is described in separate patient information leaflets. Ask your doctor to give you information about these other medicines.
Do not take Tyverb
Take special care with Tyverb
Your doctor will run tests to check that your heart is working properly before and during your treatment with Tyverb.
Tell your doctor if you have any heart problems before you take Tyverb.
Your doctor also needs to know before you take Tyverb:
Your doctor will run tests to check that your liver is working properly before and during your treatment with Tyverb.
Tell your doctor if any of these apply to you.
Serious skin reactions Serious skin reactions have been seen with Tyverb. Symptoms may include skin rash, blisters and skin peeling.
Tell your doctor as soon as possible if you get any of these symptoms.
Other medicines and Tyverb Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes herbal medicines and other medicines you bought without a prescription.
It is especially important to tell your doctor if you are taking, or have recently taken any of the following medicines. Some medicines may affect the way Tyverb works or Tyverb may affect how other medicines work. These medicines include some medicines in the following groups:
Tell your doctor if you are taking, or have recently taken, any of these.
Your doctor will review the medicines you are currently taking to make sure you are not taking something that can t be taken with the Tyverb. Your doctor will advise you whether an alternative is available.
Tyverb with food and drink
Don t drink grapefruit juice while you are being treated with Tyverb. It can affect the way the medicine works.
Pregnancy and breast-feeding
The effect of Tyverb during pregnancy is not known. You should not use Tyverb if you are pregnant unless your doctor specifically recommends it.
It is not known whether Tyverb passes into breast-milk. Do not breast-feed while taking Tyverb and for at least 5 days after the last dose.
Ask your doctor or pharmacist for advice before taking Tyverb if you are unsure.
Driving and using machines
You are responsible to decide if you are able to drive a motor vehicle or perform other tasks that require increased concentration. Because of the possible side effects of Tyverb, your ability to drive or operate machines could be affected. These effects are described in section 4, Possible side effects .
Tyverb contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially sodium- free .
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you re not sure.
Your doctor will decide on the correct dose of Tyverb depending on the type of breast cancer being treated.
If you are prescribed Tyverb in combination with capecitabine, the usual dose is 5 Tyverb tablets a day, as a single dose.
If you are prescribed Tyverb in combination with trastuzumab, the usual dose is 4 Tyverb tablets a day, as a single dose.
If you are prescribed Tyverb in combination with an aromatase inhibitor, the usual dose is 6 Tyverb tablets a day, as a single dose.
Take the prescribed dose every day for as long as your doctor tells you to.
Your doctor will advise you about the dose of your other anti-cancer medicine, and how to take it.
Taking your tablets
While you are taking Tyverb
If you take too much Tyverb
Contact a doctor or pharmacist immediately. If possible, show them the pack.
If you forget to take Tyverb
Don t take a double dose to make up for a forgotten dose. Just take the next dose at the scheduled time.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
A severe allergic reaction is a rare side effect (may affect up to 1 in 1,000 people) and may develop rapidly. Symptoms may include:
Tell your doctor immediately if you get any of these symptoms. Don t take any more tablets.
Very common side effects (may affect more than 1 in 10 people):
diarrhoea (which may make you dehydrated and lead to more severe complications) Tell your doctor immediately at the first sign of diarrhoea (loose stool), as it is important that this is treated right away. Also tell your doctor immediately if your diarrhoea worsens. There is more advice on reducing the risk of diarrhoea at the end of section 4. * rash, dry skin, itching Tell your doctor if you get a skin rash. There is more advice on reducing the risk of skin rash at the end of section 4. Other very common side effects
loss of appetite
feeling sick (nausea)
being sick (vomiting)
tiredness, feeling weak
indigestion
constipation
sore mouth/mouth ulcers
stomach pain
trouble sleeping
back pain
pain in hands and feet
joint or back pain
a skin reaction on the palms of the hands or soles of the feet (including tingling, numbness, pain, swelling or reddening)
cough, shortness of breath
headache
nose bleed
hot flush
unusual hair loss or thinning
Tell your doctor if any of these side effects get severe or troublesome.
Common side effects (may affect up to 1 in 10 people):
In most cases, the effect on your heart will not have any symptoms. If you do experience symptoms associated with this side effect, these are likely to include an irregular heartbeat and shortness of breath.
Tell your doctor if you get any of these symptoms.
Uncommon side effects (may affect up to 1 in 100 people):
Other uncommon side effects include:
Rare side effects (may affect up to 1 in 1,000 people):
The frequency of some side effects is not known (it cannot be estimated from the available data):
If you get other side effects
Tell your doctor or pharmacist if you notice any side effects not listed in this leaflet.
Reducing the risk of diarrhoea and skin rash
Tyverb can cause severe diarrhoea
If you suffer from diarrhoea while taking Tyverb:
Tell your doctor if your diarrhoea continues.
Tyverb can cause skin rash
Your doctor will check your skin before and during treatment. To care for sensitive skin:
Tell your doctor if you get a skin rash.
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the blister or bottle and the carton.
Do not store above 30 C.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
What Tyverb contains
What Tyverb looks like and contents of the pack
Tyverb film-coated tablets are oval, biconvex, yellow film-coated, with GS XJG marked on one side.
Tyverb is supplied in either blisters packs or bottles:
Blister packs Each pack of Tyverb contains 70 or 84 tablets in aluminium foil blisters of 10 or 12 tablets each. Each foil has a perforation down the middle and can be divided into two blisters with 5 or 6 tablets in each, depending on the pack size.
Tyverb is also available in multipacks containing 140 tablets that comprise 2 packs, each containing 70 tablets.
Bottles Tyverb is also available in plastic bottles containing 70, 84, 105 or 140 tablets.
Not all pack sizes may be marketed.
Marketing Authorisation Holder Novartis Europharm Limited Vista Building Elm Park, Merrion Road Dublin 4 Ireland
Manufacturer Glaxo Wellcome S.A. Avenida de Extremadura 3 09400 Aranda de Duero Burgos Spain
Novartis Pharma GmbH Roonstra e D-90429 Nuremberg Germany
Novartis Farmac utica S.A. Gran Via de les Corts Catalanes, 08013 Barcelona Spain
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Belgi /Belgique/Belgien Novartis Pharma N.V. T l/Tel: +32 2 246 16 Lietuva SIA Novartis Baltics Lietuvos filialas Tel: +370 5 269 16
Novartis Bulgaria EOOD : +359 2 489 98 Luxembourg/Luxemburg Novartis Pharma N.V. T l/Tel: +32 2 246 16 esk republika Novartis s.r.o. Tel: +420 225 775 Magyarorsz g Novartis Hung ria Kft. Tel.: +36 1 457 65 Danmark Novartis Healthcare A/S Tlf: +45 39 16 84 Malta Novartis Pharma Services Inc. Tel: +356 2122 2Deutschland Novartis Pharma GmbH Tel: +49 911 273 0
Nederland Novartis Pharma B.V. Tel: +31 88 04 52 Eesti SIA Novartis Baltics Eesti filiaal Tel: +372 66 30 Norge Novartis Norge AS Tlf: +47 23 05 20
Novartis (Hellas) A.E.B.E. : +30 210 281 17 sterreich Novartis Pharma GmbH Tel: +43 1 86 6Espa a Novartis Farmac utica, S.A. Tel: +34 93 306 42 Polska Novartis Poland Sp. z o.o. Tel.: +48 22 375 4France Novartis Pharma S.A.S. T l: +33 1 55 47 66 Portugal Novartis Farma - Produtos Farmac uticos, S.A. Tel: +351 21 000 8Hrvatska Novartis Hrvatska d.o.o. Tel. +385 1 6274 Rom nia Novartis Pharma Services Romania SRL Tel: +40 21 31299 Ireland Novartis Ireland Limited Tel: +353 1 260 12 Slovenija Novartis Pharma Services Inc. Tel: +386 1 300 75 sland Vistor hf. S mi: +354 535 7Slovensk republika Novartis Slovakia s.r.o. Tel: +421 2 5542 5Italia Novartis Farma S.p.A. Tel: +39 02 96 54 1 Suomi/Finland Novartis Finland Oy Puh/Tel: +358 (0)10 6133
Novartis Pharma Services Inc. : +357 22 690 Sverige Novartis Sverige AB Tel: +46 8 732 32 Latvija SIA Novartis Baltics Tel: +371 67 887 United Kingdom (Northern Ireland) Novartis Ireland Limited Tel: +44 1276 698This leaflet was last revised in
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-98293235ce75cd341e491c62f161e333
Resource Composition:
Generated Narrative: Composition composition-en-98293235ce75cd341e491c62f161e333
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/07/440/001-007status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - tyverb
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp98293235ce75cd341e491c62f161e333
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp98293235ce75cd341e491c62f161e333
identifier:
http://ema.europa.eu/identifier
/EU/1/07/440/001-007type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Tyverb 250 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en